JPM26: Sanofi’s CEO Keen To Buy the Dip as Vaccine Rhetoric Impacts Short-Term Sales

Why It Matters

The acquisitions position Sanofi to offset short‑term sales softness and capture future growth in adult vaccine segments, reshaping the competitive landscape amid political headwinds.

Key Takeaways

• Sanofi offers $2.2B for Dynavax’s HepB vaccine.
• Legacy vaccine sales dropped 8% in Q3 2025.
• Adult vaccine focus aims to bypass anti‑vaccine sentiment.
• Flu‑COVID combo targets over‑65s for high‑dose protection.
• Hudson signals more vaccine acquisitions despite political uncertainty.

Pulse Analysis

Sanofi’s aggressive vaccine‑focused M&A strategy reflects a broader industry shift toward adult immunizations, a segment less vulnerable to the anti‑vaccine narratives that have rattled U.S. public health discourse. By securing Dynavax’s Heplisav‑B, Sanofi not only diversifies its portfolio but also leverages a product with proven adult demand, mitigating the impact of declining legacy vaccine sales. This move underscores how pharmaceutical leaders are using strategic acquisitions to navigate short‑term market turbulence while positioning for long‑term revenue streams.

The $2.2 billion Dynavax deal follows Sanofi’s 2025 acquisition of Vicebio for $1.6 billion, adding a combination RSV/hMPV vaccine to its pipeline. Both assets are slated for launch several years out, aligning with the company’s expectation that future administrations will present a more favorable regulatory environment. Hudson’s comments suggest that the current political climate, while creating immediate sales softness, also reduces competition for deals, giving Sanofi a pricing advantage and a broader foothold in the adult vaccine market.

Looking ahead, Sanofi’s upcoming flu‑COVID combination shot—licensed from Novavax—targets the over‑55 and over‑65 demographics, a group seeking high‑dose protection without mRNA technology. Anticipated regulatory review in 2027‑28 could unlock a new revenue pillar, especially as older adults remain motivated to protect themselves against seasonal flu and COVID‑19. If successful, the combo could revitalize Sanofi’s vaccine franchise, offsetting current declines and setting a precedent for non‑mRNA, single‑dose solutions in a post‑pandemic market.